Howarth, Alison

3rd year PhD student

University of Portsmouth, UK

I am a 3rd year PhD student, studying novel and repurposed therapeutics for the treatment of paediatric high grade glioma.  I have carried out a genome wide CRISPR-Cas9 screen to determine essential survival genes, and with an additional low dose antidepressant, we aim to identify novel sensitivities for therapeutic effect.

Previously, I have worked as team leader in the primary pharmacology group (Pfizer, UK) and more recently in the target discovery institute (TDI) high throughput screening group (University of Oxford).

 

Existing collaborations relevant to drug delivery

Daniel Ebner, Dr. Dylan Jones and Dr. Georgina Berridge at the Target Discovery Institute (TDI), University of Oxford for CRISPR-Cas9 screening, mass spectrometry and bioinformatics.

Professor Geoff Higgins and James Coates at CRUK/MRC Oxford Institute for Radiation Oncology for metabolic studies.

Dr. Ruman Rahman and Dr. Anbarasu Lourdusamy, Children’s Brain Tumour Research Centre (CBTRC), Nottingham, for bioinformatics and tissue microarray screening. 

Publications relevant to drug delivery

Howarth A, Simms C, Kerai N, Hajluk K, Sokratous G, Cragg S, Lee SY, Morley AD, Keyoumars A, Pilkington G, Hill R. Recently identified anti-cancer compounds show promise to treat high grade gliomas in newly developed in vitro models. Manuscript under review, April 2018 – Scientific reports.

Howarth A, Pilkington G, Hill R. Modulation of Autophagy as a Therapeutic Approach for the Treatment of Paediatric High Grade Glioma. Manuscript submitted, April 2018 – Brain Pathology.

 


 Email for contact details